secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001213900-25-011315
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal appoints James J. Ferguson as CMO; Dr. Douglas Losordo departs
-----------------------------------------------------------------------

- Dr. Ferguson, over 25 years cardiovascular experience, appointed Chief Medical Officer effective Feb 5, 2025.
- Annual base salary of $505,000; discretionary bonus up to 40% of base; option grant of 60,000 shares.
- Dr. Losordo separated amicably; severance includes 6-month salary continuation, bonus, and accelerated vesting.
- Dr. Ferguson to lead late-stage clinical development of tecarfarin including pivotal LVAD trial.
- Compensation includes option vesting: 25% on Mar 1, 2026, balance pro rata over 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/ea0230166-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-011315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer